Open Access Full Text Article

RETRACTION

miR-488 Inhibits Cell Growth and Metastasis in Renal Cell Carcinoma by Targeting HMGN5 [Retraction]

Wei X, Yu L, Kong K. *Onco Targets Ther.* 2018;11:2205–2216.

The Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article. It came to the journals attention that the article contained instances of alleged image manipulation. Specifically:

- Figure 3A panel 786-O miR-NC appears to be duplicated with panel A498 miR-NC which has been rotated clockwise by ~90°.
- Figure 3B panel 786-O miR-NC appears to be duplicated with panel A498 miR-NC which has been rotated clockwise by ~45° and had some elements altered.
- Figure 3B panel 786-O miR-488 appears to be duplicated with panel A498 miR-488 which has been rotated clockwise by ~90°.

- The western blots for Figure 5A panel 786-O HMGN5 appear to be duplicated with Figure 5F panel 786-O N-cadherin.
- The western blots for Figure 5A panel A498 HMGN5 appear to be duplicated with Figure 5F panel A498 N-cadherin.

We tried to contact the authors but despite several attempts received no response. The Editor has determined the findings of the study are no longer valid and requested for the article to be retracted.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S318644

Received: 4 May 2021 Accepted: 4 May 2021 Published: 20 May 2021

OncoTargets and Therapy 2021:14 3351

335 I

© 2021 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).